Mucinex®

DRUG4 trials

Sponsors

Massachusetts Eye and Ear Infirmary, Reckitt Benckiser LLC, Reckitt Benckiser Inc.

Conditions

Filamentary KeratitisHealthy Subjects

Phase 1

Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet

CompletedNCT03633487

Reckitt Benckiser LLCHealthy Subjects

Start: 2011-10-11End: 2011-10-15Updated: 2019-02-28

Mucinex® ER 600 mg Bi-layer Tablet Versus Guaifenesin Immediate Release (IR) 200 mg q4h

CompletedNCT03642262

Reckitt Benckiser Inc.Healthy Subjects

Start: 2013-06-02End: 2013-08-09Updated: 2019-06-17

Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted

CompletedNCT03649750

Reckitt Benckiser LLCHealthy Subjects

Start: 2013-05-29End: 2013-08-07Updated: 2019-03-27

Unknown Phase

Mucinex® for Treatment of Filamentary Keratitis

CompletedNCT02859246

Massachusetts Eye and Ear InfirmaryFilamentary Keratitis

Start: 2016-09-30End: 2018-07-31Updated: 2020-02-19